Plasminogen activator and matrix metalloproteinase production and extracellular matrix degradation by rat prostate cancer cells in vitro: Correlation with metastatic behavior in vivo

Prostate

Volumn 32, Issue 3, 1997, Pages 196-204

  Quax, P H A ^a   De Bart, A C W ^a   Schalken, J A ^b   Verheijen, J H ^a  

^a TNO   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cancer; Extracellular matrix; Matrix metallo proteinase; Prostate; Urokinase type plasminogen activator

Indexed keywords

MATRIX METALLOPROTEINASE; PLASMINOGEN ACTIVATOR; UROKINASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; DNA PROBE; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; RAT;

ANALYSIS OF VARIANCE; ANIMALS; BLOTTING, NORTHERN; DNA, COMPLEMENTARY; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION, NEOPLASTIC; MALE; METALLOENDOPEPTIDASES; NEOPLASM METASTASIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATORS; PROSTATE; PROSTATIC NEOPLASMS; RATS; RATS, INBRED STRAINS; RECEPTORS, CELL SURFACE; RNA, MESSENGER; TISSUE PLASMINOGEN ACTIVATOR; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0030838465     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(19970801)32:3<196::AID-PROS6>3.0.CO;2-J     Document Type: Article

References (42)

1. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS, Skriver L: Plasminogen activators tissue degradation and cancer. Adv Cancer Res 1985;44:139-264.
2. Stetler-Stevenson WG, Liotta LA, Kleiner DE: Role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J 1993;7:1434-1441.
3. De Vries TJ, Quax PHA, Denijn M, Verrijp KN, Verheijen JH, Verspaget HW, Weidle UH, Ruiter DJ, van Muijen GNP: Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 1994;144:70-81.
4. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Jennelly JJ, Andreasen P: Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res 1990; 50:6827-6829.
5. Sier CFM, Vloedgraven HJM, Ganesh S, Griffioen G, Quax PHA, Verheijen JH, Dooijewaard G, Welvaart K, Vandevelde CJH, Lamers CBHW, Verspaget HW: Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology 1994;107:1449-1456.
6. Jänicke F, Schmitt M, Pache L, Ulm K, Harbeck N, Hofler H, Graeff H: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 1993;24:195-208.
7. Ossowski L, Reich E: Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 1983;35:611-619.
8. Mignatti P, Robbins E, Rifkin DB: Tumor invasion through the human amniotic membrane: Requirement for a proteinase cascade. Cell 1986;47:487-498.
9. Tryggvason K, Hoyhtya M, Salo T: Proteolytic degradation of extracellular matrix in tumor invasion. Biochim Biophys Acta 1987;907:191-217.
10. Cottam DW, Rees RC: Regulation of matrix metalloproteinases - Their role in tumor invasion and metastasis - Review. Int J Oncol 1993;2:861-872.
11. McDonnell S, Wright JH, Gaire M, Matrisian LM: Expression and regulation of stromelysin and matrilysin by growth factors and oncogenes. Biochem Soc Trans 1994;22:58-63.
12. Sato H, Kida Y, Mai M, Endo Y, Sasaki T, Tanaka J, Seiki M: Expression of genes encoding type-IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene 1992;7:77-83.
13. Quax PHA, van Leeuwen RTJ, Verspaget HW, Verheijen JH: Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines. Cancer Res 1990;50:1488-1494.
14. Quax PHA, van Muijen GNP, Weening-Verhoeff EJD, Lund LR, Danø K, Ruiter DJ, Verheijen JH: Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation. J Cell Biol 1991;115:191-199.
15. Wilson MJ: Proteases in prostate development, function and pathology. Microsc Res Techn 1995;30:305-318.
16. Keer HN, Gaylis FD, Kozlowski JM, Kwaan HC, Bauer KD, Sinha AA, Wilson MJ: Heterogeneity in plasminogen activator (PA) levels in human prostate cancer cell lines: Increased PA activity correlates with biologically aggressive behavior. Prostate 1991;18:201-214.
17. Wilson MJ, Sinha AA: Plasminogen activator and metalloprotease activities of Du-145, PC-3 and 1-LN-PC-3-1A human prostate tumors grown in nude mice - Correlation with tumor invasive behavior. Cell Mol Biol Res 1993;39:751-760.
18. Crowley CW, Cohen RL, Lucas BK, Liu GH, Shuman MA: Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 1993;90:5021-5025.
19. Hoosein NM, Boyd D, Hollas W, Mazar A, Henkin J, Chung LWK: Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Com 1991;3:255-264.
20. Jarrard DF, Hansen NM, Patai B, Ruksalis DB: Urokinase plasminogen activator is necessary but not sufficient for prostate cancer cell invasion. Invasion Metastasis 1995;15:34-45.
21. Dunning WF: Model systems for the study of prostatic cancer. NCI Monogr 1963;12:351-369.
22. Isaacs JT, Isaacs WB, Feitz WFJ, Scheres J: Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 1986;9:261-281.
23. Lowe FC, Isaacs JT: Biochemical methods for predicting metastatic ability of prostatic cancer utilizing the Dunning R-3327 rat prostatic adenocarcinoma system as a model. Cancer Res 1984; 44:744-752.
24. Bussemakers MJG, van Moorselaar RJA, Giroldi LA, Ichikawa T, Isaacs JT, Takeichi M, Debruyne FMJ, Schalken JA: Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res 1992;52:2916-2922.
25. Schalken JA, Ebeling SB, Isaacs JT, Treiger B, Bussemakers MJG, Dejong MEM, van de Ven WJM: Down modulation of fibronectin messenger RNA in metastasizing rat prostatic cancer cells revealed by differential hybridization analysis. Cancer Res 1988; 48:2042-2046.
26. Hierowski MT, Schally AV: An inhibitor of urokinase and tissue plasminogen activators in Dunning R3327H prostate tumors of rats treated with D-Trp6-LH-RH. Horm Res 1985;21:124-135.
27. Sier CFM, Verspaget HW, Griffioen G, Verheijen JH, Quax PHA, Dooijewaard G, De Bruin PAF, Lamers CBHW: Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia: Implications of urokinase in colorectal carcinogenesis. Gastroenterology 1991;101:1522-1528.
28. Granelli-Piperno A, Reich E: A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 1978;148: 223-234.
29. Verheijen JH, Mullaart E, Chang GTG, Kluft C, Wijngaards G: A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemost 1982;48:266-269.
30. Rijken DC, Wijngaards G, Welbergen J: Immunological characterization of plasminogen activator activities in human tissues and body fluids. Lab Clin Med 1981;97:477-486.
31. Binnema DJ, van Iersel JJL, Dooijewaard G: Quantitation of urokinase antigen in plasma and culture media by use of an ELISA. Thromb Res 1986;43:569-577.
32. Gaffney PJ, Heath AB: A collaborative study to establish a standard for high molecular weight urinary-type plasminogen activator (HMW/u-PA). Thromb Haemost 1990;64:398-401.
33. Gaffney PJ, Curtis AD: A collaborative study of a proposed international standard for tissue plasminogen activator (t-PA). Thromb Haemost 1985;53:134-136.
34. Hanemaaijer R, Koolwijk P, Leclercq L, Devree WJA, van Hinsbergh VWM: Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells - Effects of tumour necrosis factor-alpha, interleukin-1 and phorbol ester. Biochem J 1993;296:803-809.
35. Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidnium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
36. Zeheb R, Gelehrter TD: Cloning and sequencing of cDNA for the rat plasminogen activator inhibitor-1. Gene 1988;73:459-468.
37. Belin D, Wohlwend A, Schleuning WD, Kruithof EKO, Vassalli JD: Facultative polypeptide translocation allows a single messenger RNA to encode the secreted and cytosolic forms of plasminogen activators inhibitor-2. EMBO J 1989;8:3287-3294.
38. De Bart ACW, Quax PHA, Löwik CWGM, Verheijen JH: Regulation of plasminogen activation, matrix metalloproteinases and urokinase-type plasminogen activator-mediated extracellular matrix degradation in human osteosarcoma cell line MG63 by interleukin-1 alpha. J Bone Miner Res 1995;10:1374-1384.
39. 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem 1992;267:14543-14546.
40. Kirchheimer JC, Koller A, Binder BR: Isolation and characterization of plasminogen activators from hyperplastic and malignant prostate tissue. Biochim Biophys Acta 1984;797:256-265.
41. Kirchheimer JC, Pfluger H, Ritschl P, Hienert G, Binder BR: Plasminogen activator activity in bone metastasis of prostatic carcinomas as compared to primary tumors. Invasion Metastasis 1985;5:344-355.
42. Wilson MJ, Kapoor S, Vogel MM, Sinha AA: Characterization of gelatin degrading metalloproteinase activities of the Dunning rat prostate tumor grown in nude mice. Prostate 1991;19:237-250.